Cytomegalovirus Infections in Solid Organ Transplantation: A Review

키워드

참고문헌 (87)

1. Fishman JA, "Overview: cytomegalovirus and the herpesvirusesin transplantation", Am J Transplant, 13(3), pp.1~8 (2013)
2. Craig JM, "Isolationof intranuclear inclusion producing agents from infantswith illnesses resembling cytomegalic inclusion disease", Proc Soc Exp Biol Med, 94, pp.4~12 (1957)
3. Smith MG, "Propagation in tissue cultures of a cytopathogenicvirus from human salivary gland virus (SGV) disease", Proc Soc Exp Biol Med, 92, pp.424~430 (1956)
4. Boeckh M, "Cytomegalovirus: pathogen, paradigm,and puzzle", J Clin Invest, 121, pp.1673~1680 (2011)
5. Cannon MJ, "Review of cytomegalovirusseroprevalence and demographic characteristics associatedwith infection", Rev Med Virol, 20, pp.202~213 (2010)
6. Bate SL, "Cytomegalovirus seroprevalencein the United States: the national health and nutritionexamination surveys, 1988-2004", Clin Infect Dis, 50, pp.1439~1447 (2010)
7. Harvala H, "High risk of cytomegalovirusinfection following solid organ transplantation despiteprophylactic therapy", J Med Virol, 85, pp.893~898 (2013)
8. Mendez-Eirin E, "Cumulative incidence of cytomegalovirus infectionand disease after heart transplantation in the last decade: effect of preemptive therapy", Transplant Proc, 44, pp.2660~2662 (2012)
9. Hammond SP, "Cytomegalovirusdisease in lung transplantation: impact of recipientseropositivity and duration of antiviral prophylaxis", Transpl Infect Dis, 15, pp.163~170 (2013)
10. Eid AJ, "New developments in the managementof cytomegalovirus infection after solid organ transplantation", Drugs, 70, pp.965~981 (2010)
11. Arthurs SK, "Delayed-onset primary cytomegalovirusdisease and the risk of allograft failure and mortalityaf ter kidney t ransplantat ion", Cl in Infect Dis, 46, pp.840~846 (2008)
12. Razonable RR, "Strategies for managing cytomegalovirusin transplant recipients", Expert Opin Pharmacother, 11, pp.1983~1997 (2010)
13. Gordon CR, "Cytomegalovirusand other infectious issues related to facetransplantation: specific considerations, lessons learned,and future recommendations", Plast Reconstr Surg, 127, pp.1515~1523 (2011)
14. Razonable RR, "AST Infectious Diseases Communityof Practice. Cytomegalovirus in solid organ transplantation", Am J Transplant, 13(4), pp.93~106 (2013)
15. Fishman JA, "Infection in solid-organ transplant recipients", N Engl J Med, 357, pp.2601~2614 (2007)
16. Luan FL, "Six-month low-dose valganciclovir prophylaxisin cytomegalovirus D+", R- kidney transplant patients receivingthymoglobulin induction, 2013, pp.45, 175~177
17. Requiao-Moura LR, "Comparisonof long-term effect of thymoglobulin treatment in patientswith a high risk of delayed graft function", Transplant Proc, 44, pp.2428~2433 (2012)
18. Razonable RR, "Allograftrejection predicts the occurrence of late-onset cytomegalovirus(CMV) disease among CMV-mismatchedsolid organ transplant patients receiving prophylaxis withoral ganciclovir", J Infect Dis, 184, pp.1461~1464 (2001)
19. Brennan DC, "Cytomegalovirus incidence betweeneverolimus versus mycophenolate in de novo renaltransplants: pooled analysis of three clinical trials", Am JTransplant, 11, pp.2453~2462 (2011)
20. Humar A, "VICTOR study group. An assessment of herpesvirusco-infections in patients with CMV disease: correlationwith clinical and virologic outcomes", Am J Transplant, 9, pp.374~381 (2009)
21. Manuel O, "Associationbetween mannose-binding lectin deficiency andcytomegalovirus infection after kidney transplantation", Transplantation, 83, pp.359~362 (2007)
22. Kwakkel-van Erp JM, "Otten HG.Mannose-binding lectin deficiency linked to cytomegalovirus(CMV) reactivation and survival in lung transplantation", Clin Exp Immunol, 165, pp.410~416 (2011)
23. Krishnan A, "Programmed death-1 receptor and interleukin-10 in liver transplant recipients at high risk for late cytomegalovirusdisease", Transpl Infect Dis, 12, pp.363~370 (2010)
24. Cummins NW, "Deficiencyof cytomegalovirus (CMV)-specific CD8+ T cellsin patients presenting with late-onset CMV disease severalyears after transplantation", Transpl Infect Dis, 11, pp.20~27 (2009)
25. Weseslindtner L, "Prospective analysisof human cytomegalovirus DNAemia and specific CD8+ Tcell responses in lung transplant recipients", Am J Transplant, 12, pp.2172~2180 (2012)
26. Razonable RR, "Cytomegalovirus infection after liver transplantation:current concepts and challenges", World J Gastroenterol, 14, pp.4849~4860 (2008)
27. La Rosa C, "The immune response to humanCMV", Future Virol, 7, pp.279~293 (2012)
28. Kijpittayarit S, "Relationship between Toll-like receptor 2 polymorphismand cytomegalovirus disease after liver transplantation", Clin Infect Dis, 44, pp.1315~1320 (2007)
29. Kang SH, "Homozygosity for the tolllikereceptor 2 R753Q single-nucleotide polymorphism isa risk factor for cytomegalovirus disease after liver transplantation", J Infect Dis, 205, pp.639~646 (2012)
30. Humar A, "AST ID Working Group on InfectiousDisease Monitoring. Humar A American Society ofTransplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppressiontrials in recipients of organ transplantation", Am J Transplant, 6, pp.262~274 (2006)
31. Paya C, "ValganciclovirSolid Organ Transplant Study Group. Efficacyand safety of valganciclovir vs. oral ganciclovir for preventionof cytomegalovirus disease in solid organ transplantrecipients", Am J Transplant, 4, pp.611~620 (2004)
32. Freeman RB Jr, "The ‘indirect’ effects of cytomegalovirusinfection", Am J Transplant, 9, pp.2453~2458 (2009)
33. Kotton CN, "CMV: Prevention, Diagnosis and Therapy", AmJ Transplant, 13(3), pp.24~40 (2013)
34. Falagas ME, "Exposureto cytomegalovirus from the donated organ is a risk factorfor bacteremia in orthotopic liver transplant recipients.Boston Center for Liver Transplantation CMVIG StudyGroup", Clin Infect Dis, 23, pp.468~474 (1996)
35. George MJ, "The independent role ofcytomegalovirus as a risk factor for invasive fungal diseasein orthotopic liver transplant recipients. Boston Center forLiver Transplantation CMVIG-Study Group. Cytogam,MedImmune, Inc", Am J Med, 103, pp.106~113 (1997)
36. Chopra KB, "Progression of liver fibrosis in patients with chronichepatitis C after orthotopic liver transplantation", Transplantation, 76, pp.1487~1491 (2003)
37. Walker RC, "Pretransplantationassessment of the risk of lymphoproliferativedisorder", Clin Infect Dis, 20, pp.1346~1353 (1995)
38. Madalosso C, "Cytomegalovirus and its association with hepaticartery thrombosis after liver transplantation", Transplantation, 66, pp.294~297 (1998)
39. Sagedal S, "Theimpact of cytomegalovirus infection and disease on rejectionepisodes in renal allograft recipients", Am J Transplant, 2, pp.850~856 (2002)
40. Streblow DN, "Acceleration of allograftfailure by cytomegalovirus", Curr Opin Immunol, 19, pp.577~582 (2007)
41. Potena L, "Cytomegalovirus-associatedallograft rejection in heart transplant patients", Curr OpinInfect Dis, 20, pp.425~431 (2007)
42. Thomas LD, "Long-term outcomes of cytomegalovirus infectionand disease after lung or heart-lung transplantationwith a delayed ganciclovir regimen", Clin Transplant, 23, pp.476~483 (2009)
43. Leung Ki EL, "Cytomegalovirus infection and new-onset post-transplantdiabetes mellitus", Clin Transplant, 22, pp.245~249 (2008)
44. Hayden RT, "College of AmericanPathologists Microbiology Resource Committee. Factorscontributing to variability of quantitative viral PCRresults in proficiency testing samples: a multivariate analysis", J Clin Microbiol, 50, pp.337~345 (2012)
45. Kraft CS, "Interpreting quantitativecytomegalovirus DNA testing: understanding thelaboratory perspective", Clin Infect Dis, 54, pp.1793~1797 (2012)
46. Pang XL, "American Society of Transplantation InfectiousDiseases Community of Practice; Canadian Society ofTransplantation. Interlaboratory comparison of cytomegalovirusviral load assays", Am J Transplant, 9, pp.258~268 (2009)
47. Lisboa LF, "The clinical utility of whole blood versus plasma cytomegalovirusviral load assays for monitoring therapeutic response", Transplantation, 91, pp.231~236 (2011)
48. Hirsch HH, "An internationalmulticenter performance analysis of cytomegalovirusload tests", Clin Infect Dis, 56, pp.367~373 (2013)
49. Razonable RR, "Virologic suppressionmeasured by a cytomegalovirus (CMV) DNA test calibratedto the world health organization internationalstandard is predictive of CMV disease resolution in transplantrecipients", Clin Infect Dis, 56, pp.1546~1553 (2013)
50. Humar A, "Valganciclovir SolidOrgan Transplant Study Group. Clinical utility of cytomegalovirus(CMV) serology testing in high-risk CMV D+", R- transplant recipients, 2005, pp.5, 1065~1070
51. Razonable RR, "Role of the laboratory indiagnosis and management of cytomegalovirus infectionin hematopoietic stem cell and solid-organ transplant recipients", J Clin Microbiol, 40, pp.746~752 (2002)
52. Lisboa LF, "Clinical utilityof cytomegalovirus cell-mediated immunity in transplantrecipients with cytomegalovirus viremia", Transplantation, 93, pp.195~200 (2012)
53. Manuel O, "Assessment of cytomegalovirus-specific cellmediatedimmunity for the prediction of cytomegalovirusdisease in high-risk solid-organ transplant recipients: amulticenter cohort study", Clini Infect Dis, 56, pp.817~824 (2013)
54. Kumar D, "Cell-mediatedimmunity to predict cytomegalovirus disease in high-risksolid organ transplant recipients", Am J Transplant, 9, pp.1214~1222 (2009)
55. Egli A, "State-of-the-art monitoring ofcytomegalovirus-specific cell-mediated immunity afterorgan transplant: a primer for the clinician", Clin Infect Dis, 55, pp.1678~1689 (2012)
56. Humar A, "The efficacy and safety of 200days valganciclovir cytomegalovirus prophylaxis in highriskkidney transplant recipients", Am J Transplant, 10, pp.1228~1237 (2010)
57. Palmer SM, "Extended valganciclovir prophylaxisto prevent cytomegalovirus after lung transplantation:a randomized, controlled trial", Ann Intern Med, 152, pp.761~769 (2010)
58. Finlen Copeland CA, "Long-term efficacy and safetyof 12 months of valganciclovir prophylaxis compared with3 months after lung transplantation: a single-center, longtermfollow-up analysis from a randomized, controlledcytomegalovirus prevention trial", J Heart Lung Transplant, 30, pp.990~996 (2011)
59. Zuk DM, "An international survey of cytomegalovirus managementpractices in lung transplantation", Transplantation, 90, pp.672~676 (2010)
60. Wiita AP, "Cytomegalovirus disease and infectionin lung transplant recipients in the setting of plannedindefinite valganciclovir prophylaxis", Transpl Infect Dis, 14, pp.248~258 (2012)
61. Weill D, "Combination prophylaxis withganciclovir and cytomegalovirus (CMV) immune globulinafter lung transplantation: effective CMV prevention followingdaclizumab induction", Am J Transplant, 3, pp.492~496 (2003)
62. Bonaros N, "CMV-hyperimmune globulin for preventing cytomegalovirusinfection and disease in solid organ transplant recipients:a meta-analysis", Clin Transplant, 22, pp.89~97 (2008)
63. Kotton CN, "Transplantation SocietyInternational CMV Consensus Group. International consensusguidelines on the management of cytomegalovirusin sol id organ t ransplantat ion", Transplantat ion, 89, pp.779~795 (2010)
64. Abate D, "Evaluationof cytomegalovirus (CMV)-specific T cell immune reconstitutionrevealed that baseline antiviral immunity,prophylaxis, or preemptive therapy but not antithymocyteglobulin treatment contribute to CMV-specific T cell reconstitutionin kidney transplant recipients", J Infect Dis, 202, pp.585~594 (2010)
65. Kalil AC, "Metaanalysis:the efficacy of strategies to prevent organ diseaseby cytomegalovirus in solid organ transplant recipients", Ann Intern Med, 143 (2005)
66. Martin-Gandul C, "Spanish Network for Research in Infectious Diseases. Determination,validation and standardization of a CMVDNA cut-off value in plasma for preemptive treatment ofCMV infection in solid organ transplant recipients at lowerrisk for CMV infection", J Clin Virol, 56, pp.13~18 (2013)
67. Owers DS, "Pre-emptive treatment for cytomegalovirus viraemia to preventcytomegalovirus disease in solid organ transplant recipients", Cochrane Database of Syst Rev, 2, pp.CD005133~ (2013)
68. Kliem V, "Improvement in long-term renal graft survivaldue to CMV prophylaxis with oral ganciclovir: results of arandomized clinical trial", Am J Transplant, 8, pp.975~983 (2008)
69. Limaye AP, "High incidence of ganciclovir-resistant cytomegalovirusinfection among lung transplant recipientsreceiving preemptive therapy", J Infect Dis, 185, pp.20~27 (2002)
70. Eid AJ, "Emergence of drug-resistant cytomegalovirus in the era ofvalganciclovir prophylaxis: therapeutic implications andoutcomes", Clin Transplant, 22, pp.162~170 (2008)
71. Myhre HA, "Incidence and outcomesof ganciclovir-resistant cytomegalovirus infectionsin 1244 kidney transplant recipients", Transplantation, 92, pp.217~223 (2011)
72. Couzi L, "High incidenceof anticytomegalovirus drug resistance amongD+R- kidney transplant recipients receiving preemptivetherapy", Am J Transplant, 12, pp.202~209 (2012)
73. Boivin G, "Incidenceof cytomegalovirus UL97 and UL54 amino acid substitutionsdetected after 100 or 200 days of valganciclovir prophylaxis", J Clin Virol, 53, pp.208~213 (2012)
74. Griffiths PD, "Cytomegalovirus glycoprotein-B vaccinewith MF59 adjuvant in transplant recipients: a phase2 randomi sed placebo-cont rol led t r ial", Lance, 377, pp.1256~1263 (2011)
75. Lisboa LF, "Clinical utilityof molecular surveillance for cytomegalovirus after antiviralprophylaxis in high-risk solid organ transplant recipients", Transplantation, 92, pp.1063~1068 (2011)
76. Dunn DL, "Treatment of invasive cytomegalovirusdisease in solid organ transplant patients with ganciclovir", Transplantation, 51, pp.98~106 (1991)
77. Keay S, "Ganciclovir treatmentof serious cytomegalovirus infection in heart andheart-lung transplant recipients", Rev Infect Dis, 10(3), pp.S563~S572 (1988)
78. Asberg A, "VICTOR Study Group. Oral valganciclovir is noninferiorto intravenous ganciclovir for the treatment of cytomegalovirusdisease in solid organ transplant recipients", Am J Transplant, 7, pp.2106~2113 (2007)
79. Humar A, "Cytomegalovirus(CMV) virus load kinetics to predict recurrent diseasein solid-organ transplant patients with CMV disease", J Infect Dis, 186, pp.829~833 (2002)
80. Sia IG, "Cytomegalovirus (CMV) DNA load predicts relapsingCMV infection after solid organ transplantation", J InfectDis, 181, pp.717~720 (2000)
81. Li F, "Incidence and clinical features of ganciclovir-resistantcytomegalovirus disease in heart transplant recipients", Clin Infect Dis, 45, pp.439~447 (2007)
82. Lurain NS, "Antiviral drug resistance of human cytomegalovirus", Clin Microbiol Rev, 23, pp.689~712 (2010)
83. Le Page AK, "Clinical aspects of cytomegalovirus antiviralresistance in solid organ transplant recipients", ClinInfect Dis, 56 (2013)
84. Limaye AP, "Emergence of ganciclovir-resistant cytomegalovirus diseaseamong recipients of solid-organ transplants", Lancet, 356, pp.645~649 (2000)
85. Emery VC, "Prediction of cytomegalovirusload and resistance patterns after antiviral chemotherapy", Proc Natl Acad Sci U S A, 97, pp.8039~8044 (2000)
86. Boivin G, "Cytomegalovirusresistance in solid organ transplant recipients treated withintravenous ganciclovir or oral valganciclovir", Antivir Ther, 14, pp.697~704 (2009)
87. Sabe N, "Successful outcomeof ganciclovir-resistant cytomegalovirus infection inorgan transplant recipients after conversion to mTOR inhibitors", Transpl Int, 25, pp.e78~e82 (2012)

관련 논문AI추천